CN100350242C - Determination method of naringoside content in stomach intestine calm pill - Google Patents

Determination method of naringoside content in stomach intestine calm pill Download PDF

Info

Publication number
CN100350242C
CN100350242C CNB2005100148809A CN200510014880A CN100350242C CN 100350242 C CN100350242 C CN 100350242C CN B2005100148809 A CNB2005100148809 A CN B2005100148809A CN 200510014880 A CN200510014880 A CN 200510014880A CN 100350242 C CN100350242 C CN 100350242C
Authority
CN
China
Prior art keywords
solution
gastrointestinal disease
disease treating
assay method
treating pill
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2005100148809A
Other languages
Chinese (zh)
Other versions
CN1758058A (en
Inventor
凌宁生
杨瑾
律兆荣
刘志宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lerentang Pharmaceutical Factory Of Jinyao Darentang Group Co ltd
Original Assignee
Lerentang Pharmaceutical Factory of Tianjin Zhongxin Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lerentang Pharmaceutical Factory of Tianjin Zhongxin Pharmaceutical Group Co Ltd filed Critical Lerentang Pharmaceutical Factory of Tianjin Zhongxin Pharmaceutical Group Co Ltd
Priority to CNB2005100148809A priority Critical patent/CN100350242C/en
Publication of CN1758058A publication Critical patent/CN1758058A/en
Application granted granted Critical
Publication of CN100350242C publication Critical patent/CN100350242C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The present invention discloses a method for determining naringoside contents in stomach intestine calm pills, which comprises the following steps that (1) preparing a reference substance solution that the reference substance solution can be manufactured by taking a right amount of naringoside reference substances and adding carbinol; (2) preparing a solution for test products: stomach intestine calm pills can be porphyrized, and powder can be put in a conical flask with a plug; carbinol can be added; the heating in water bath and the back flow can be carried out, and then, the solution for test products can be manufactured by chilling, precise weighing and the filtration of microporous filtering films; (3) a high performance liquid chromatograph can be adopted for measurement. The method for determining naringoside contents in stomach intestine calm pills of the present invention has the characteristics of convenience, high speed and good specificity and repeatability. The result is exact and reliable. The present invention can be used for the quality control of stomach intestine calm pills.

Description

The assay method of naringin content in the gastrointestinal disease treating pill
Technical field
The present invention relates to the assay method of naringin content in a kind of Chinese medicine preparation, particularly relate to a kind of assay method that utilizes naringin content in the high effective liquid chromatography for measuring Chinese medicine preparation gastrointestinal disease treating pill.
Background technology
At present, along with the continuous development of the modernization of Chinese medicine, the improving constantly of pharmaceutical technology (tcd) and quality testing level, increasing advanced detecting instrument and laboratory facilities are used to the detection of Chinese patent drug quality.Simultaneously, along with the raising of people's living standard, society is also more and more higher to the quality requirements of medicine, and this will have advanced person, stable, reliable detection method that the quality of medicine is effectively controlled with regard to requiring each pharmacy corporation.Therefore, the quality standard of raising Chinese patent drug is imperative.
In addition, country encourages each pharmacy corporation and R﹠D institution to improve existing Chinese patent drug quality standard, and passes through the raising that some approach promote quality standards, for example:
1.2005 " Chinese pharmacopoeia has increased qualitative, the quantitative identification method of many Chinese crude drugs and Chinese patent drug to a year version on the basis of version in 2000;
2. in the process that medicine registrations such as new product development and old product secondary development are declared, all require on the basis of initial quality standard, to improve.
Gastrointestinal disease treating pill be in the pure Chinese medicinal preparation of the treatment enterogastric diseases developed of new medicine company Lerentang Traditional Chinese Medicine Factory, Tianjin, record in " Chinese pharmacopoeia version in 2000, this prescription is made up of flavour of a drug such as the banksia rose, agalloch eaglewood, rheum officinale, Fructus Aurantiis, have eliminate dampness with aromatics, regulating qi-flowing for relieving pain has to be good for the stomach and leads stagnant merit, clinically is used for the treatment of diseases such as diarrhoea, enteritis, bacillary dysentery, gastral cavity abdomen overflow, stomachache and dyspepsia breast that indigestion causes be long-pending.Fructus Aurantii is main flavour of a drug in the prescription, plays the gas of sharp chest abdomen, the long-pending ruffian that disappears of loosing, dampness elimination and leads stagnant helping digestion.Aurantiin is one of principal ingredient in the Fructus Aurantii, and higher because of aurantiin content in the Fructus Aurantii medicinal material, therefore and stable in properties, can control this product inherent quality effectively by the monitoring to naringin content in the gastrointestinal disease treating pill.
Summary of the invention
The assay method that the purpose of this invention is to provide naringin content in a kind of gastrointestinal disease treating pill, the present invention is the content that utilizes aurantiin in the high effective liquid chromatography for measuring gastrointestinal disease treating pill, to improve the quality standard of gastrointestinal disease treating pill.
Technical scheme of the present invention is summarized as follows:
The assay method of naringin content in a kind of gastrointestinal disease treating pill, form by following steps:
(1) it is an amount of that the aurantiin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds the solution that methyl alcohol is made 0.01mg/ml~0.119mg/ml, preferably 0.01mg/ml, product solution in contrast;
(2) the gastrointestinal disease treating pill porphyrize is got in the preparation of need testing solution, and it is fixed to get the accurate title of powder 0.1g, puts 50ml tool plug conical flask, add methyl alcohol 25ml, the accurate title, decided water-bath reflux 20~90 minutes, preferably 30 minutes, put and be chilled to room temperature, the accurate title, decide, and supplies with methyl alcohol to subtract weight loss, and miillpore filter filters, as need testing solution, the miillpore filter aperture is 0.45 μ m preferably;
(3) adopt high performance liquid chromatograph to measure, chromatographic condition is: Diamonsil chromatographic column: C 18Reverse-phase chromatography column length 250mm, internal diameter 4.6mm, filler diameter are 5 μ m; Moving phase: the volume ratio of acetonitrile and 0.1%~1% glacial acetic acid aqueous solution is 10~50: 90~50, and best the concentration of described glacial acetic acid aqueous solution is concentration of volume percent than being 20: 80, and preferred concentration is 0.3%: detect wavelength: 217nm; Flow velocity: 0.5ml/min~1.0ml/min, optimum flow rate are 0.8ml/min; 20 ℃~40 ℃ of column temperatures are advisable with 35 ℃, and precision is got reference substance solution and each 5 μ l of need testing solution respectively, injects described high performance liquid chromatograph, measures.
Advantage of the present invention is: easily and fast, specificity and favorable reproducibility, the result can be used for the quality control of gastrointestinal disease treating pill accurately and reliably.
Description of drawings
Fig. 1 is the high-efficient liquid phase chromatogram of reference substance aurantiin;
Fig. 2 is the high-efficient liquid phase chromatogram of aurantiin in the gastrointestinal disease treating pill;
The high-efficient liquid phase chromatogram of the negative reference substance of Fig. 3.
Embodiment
The present invention is further illustrated below in conjunction with specific embodiment.
Embodiment 1
The assay method of naringin content comprises the steps: in a kind of gastrointestinal disease treating pill
(1) it is an amount of that the aurantiin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds the solution that methyl alcohol is made 0.01mg/ml, in contrast product solution;
(2) the gastrointestinal disease treating pill porphyrize is got in the preparation of need testing solution, it is fixed to get the accurate title of powder art 0.1g, put 50ml tool plug conical flask, add methyl alcohol 25ml, the accurate title, decide, water-bath reflux 30 minutes, put and be chilled to room temperature, the accurate title, decide, and supplies with methyl alcohol to subtract weight loss, 0.45 μ m miillpore filter filters, as need testing solution;
(3) adopt high performance liquid chromatograph to measure, chromatographic condition is: Diamonsil chromatographic column: C 18Reverse-phase chromatographic column specification: 5 μ m, 250 * 4.6mm; Moving phase: the volume ratio of acetonitrile and 0.3% glacial acetic acid aqueous solution is 20: 80, and the concentration of described glacial acetic acid aqueous solution is concentration of volume percent; Detect wavelength: 217nm; Flow velocity: 0.8ml/min; 35 ℃ of column temperatures, precision is got reference substance solution and each 5ul of need testing solution respectively, injects described high performance liquid chromatograph, measures.
Embodiment 2
The assay method of naringin content comprises the steps: in a kind of gastrointestinal disease treating pill
(1) it is an amount of that the aurantiin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds the solution that methyl alcohol is made 0.0119mg/ml, in contrast product solution;
(2) the gastrointestinal disease treating pill porphyrize is got in the preparation of need testing solution, and it is fixed to get the accurate title of powder 0.1g, puts 50ml tool plug conical flask, adds methyl alcohol 25ml, the accurate title, decide, and water-bath reflux 20 minutes is put and is chilled to room temperature, and accurate title is fixed, supply with methyl alcohol and to subtract weight loss, miillpore filter filters, as need testing solution;
(3) adopt high performance liquid chromatograph to measure, chromatographic condition is: Diamonsil chromatographic column: C 18Reverse-phase chromatographic column specification: 5 μ m, 250 * 4.6mm; Moving phase: the volume ratio of acetonitrile and 0.1% glacial acetic acid aqueous solution is 50: 50, and the concentration of described glacial acetic acid aqueous solution is concentration of volume percent; Detect wavelength: 217nm; Flow velocity: 0.5ml/min; 20 ℃ of column temperatures, precision is got reference substance solution and each 5ul of need testing solution respectively, injects described high performance liquid chromatograph, measures.
Embodiment 3
The assay method of naringin content comprises the steps: in a kind of gastrointestinal disease treating pill
(1) it is an amount of that the aurantiin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds the solution that methyl alcohol is made 0.119mg/ml, in contrast product solution;
(2) the gastrointestinal disease treating pill porphyrize is got in the preparation of need testing solution, and it is fixed to get the accurate title of powder 0.1g, puts 50ml tool plug conical flask, adds methyl alcohol 25ml, the accurate title, decide, and water-bath reflux 90 minutes is put and is chilled to room temperature, and accurate title is fixed, supply with methyl alcohol and to subtract weight loss, miillpore filter filters, as need testing solution;
(3) adopt high performance liquid chromatograph to measure, chromatographic condition is: Diamonsil chromatographic column: C 18Reverse-phase chromatographic column specification: 5 μ m, 250 * 4.6mm; Moving phase: the volume ratio of acetonitrile and 1% glacial acetic acid aqueous solution is 10: 90, and the concentration of described glacial acetic acid aqueous solution is concentration of volume percent; Detect wavelength: 217nm; Flow velocity: 1.0ml/min; 40 ℃ of column temperatures, precision is got reference substance solution and each 5ul of need testing solution respectively, injects described high performance liquid chromatograph, measures.
Embodiment 4
Accurate aurantiin reference substance solution (concentration is 0.0119mg/ml) 2,4,8,12,16, the 20 μ l sample introductions of drawing of the investigation of linear relationship, measure by above-mentioned chromatographic condition, sample size with the aurantiin reference substance is a horizontal ordinate, respective peaks area integral value is an ordinate, the calculating regression equation is Y=4666857X-15551.9, r=0.99995 (r: related coefficient).The aurantiin reference substance solution becomes good linear relationship in 0.0119~0.119mg/ml scope.
Embodiment 5
Same need testing solution is got in the precision experiment, and continuous 6 sample introductions record the peak area integrated value, and RSD (relative standard deviation) is 1.7% as a result.
Embodiment 6
Same batch sample is got in the reappearance experiment, takes by weighing 6 parts of test samples, according to need testing solution preparation method preparation, measures content, and average content is 11.38mg/g, and RSD is 1.45%, shows that this law reappearance is good, and precision is higher.
Embodiment 7
Stability experiment is got same need testing solution, and every 2 hours sample introduction 2 μ l, sample introduction was 6 times altogether, measures peak area and calculates content, and RSD is 1.7% (n=6) as a result.
Embodiment 8
The application of sample absorption method is adopted in recovery experiment, gets 6 parts in the sample of known content (11.38mg/g), accurately respectively adds a certain amount of aurantiin reference substance, measures according to content assaying method, calculates average recovery, the results are shown in Table 1.
Table 1. recovery test result
Table 1 Result of recovery test
Sample volume (g) Sample naringin content (mg) Aurantiin addition (mg) Measurement result (mg) The recovery (%) Average recovery rate (%) RSD (%)
0.0531 0.0543 0.0535 0.0533 0.0545 0.0473 0.6037 0.6181 0.6091 0.6071 0.6205 0.5378 0.5712 0.5712 0.5712 0.5712 0.5712 0.5712 1.1567 1.2008 1.1854 1.1726 1.1717 1.0850 96.8 102.0 100.9 99.0 96.5 95.8 98.5 2.59
Embodiment 9
The preparation of blank liquid takes by weighing other flavour of a drug by recipe quantity with mensuration except that Fructus Aurantii, make the preparation that does not contain Fructus Aurantii by formulation and technology, make blank liquid by the need testing solution preparation method, measurement result is seen Fig. 1, Fig. 2 and Fig. 3 illustrate that other medicinal materials and auxiliary material all do not disturb the mensuration of aurantiin.
Embodiment 10
Sample determination is got ten batches of stomach and intestine peace samples, is equipped with need testing solution by need testing solution preparation below legal system, two parts of need testing solutions of every batch of preparation.Accurate need testing solution, each 2 μ l of reference substance solution of drawing inject high performance liquid chromatograph, measure, and ten batch samples the results are shown in Table 2.
The measurement result of aurantiin in table 2 gastrointestinal disease treating pill
Table 2 Determination of Naringin in Weichang’an Pill
Lot number Naringin content (mg/g)
D109004 4.8
D109007 4.9
D109008 5.2
D109009 5.4
D109010 4.6
D109016 5.6
D109019 5.3
D109020 4.4
030681 4.6
030784 4.8
Mean value 4.98
By naringin content in ten batches of gastrointestinal disease treating pills being detected, obtaining mean value is 4.98mg/g, and the standard that the suggestion gastrointestinal disease treating pill increases measuring naringin content is decided to be: naringin content must not be less than 4.38mg/g in the gastrointestinal disease treating pill.
This assay method easily and fast, specificity and favorable reproducibility, the result can be used for the quality control of gastrointestinal disease treating pill accurately and reliably.Discuss
Extracting method is investigated: bibliographical information, aurantiin is soluble in organic solvent, and extracting method mainly contains ultrasonic and refluxing extraction, compares by adopting methyl alcohol ultrasonic Extraction and methanol eddy to extract, the result is best with the methanol eddy extraction effect, so adopt this extracting method.
The selection of moving phase: successively test methanol-water, acetonitrile-water, methyl alcohol-0.3 glacial acetic acid, acetonitrile-0.3% glacial acetic acid etc. and be moving phase, experimentize, compare the HPLC spectrogram, it is that moving phase detects that the result shows with acetonitrile-0.3% glacial acetic acid (20: 80), the sample peak separates best, so preferred acetonitrile-0.3% glacial acetic acid (20: 80) is a moving phase.

Claims (8)

1. the assay method of naringin content in the gastrointestinal disease treating pill is characterized in that being made up of following steps:
(1) it is an amount of that the aurantiin reference substance is got in the preparation of reference substance solution, and accurate the title decides, and adds the solution that methyl alcohol is made 0.01mg/ml~0.119mg/ml, in contrast product solution;
(2) the gastrointestinal disease treating pill porphyrize is got in the preparation of need testing solution, it is fixed to get the accurate title of powder 0.1g, put 50ml tool plug conical flask, add methyl alcohol 25ml, the accurate title, decide, water-bath reflux 20~90 minutes, put and be chilled to room temperature, the accurate title, decide, and supplies with methyl alcohol to subtract weight loss, miillpore filter filters, as need testing solution;
(3) adopt high performance liquid chromatograph to measure, chromatographic condition is the Diamonsil chromatographic column, C 18Reverse-phase chromatography column length 250mm, internal diameter 4.6mm, filler diameter are 5 μ m; Moving phase: the volume ratio of acetonitrile and 0.1%~1% glacial acetic acid aqueous solution is 10~50: 90~50, and the concentration of described glacial acetic acid aqueous solution is concentration of volume percent; Detect wavelength: 217nm; Flow velocity: 0.5ml/min~1.0ml/min; 20 ℃~40 ℃ of column temperatures, precision is got reference substance solution and each 5 μ l of need testing solution respectively, injects described high performance liquid chromatograph, measures.
2. the assay method of naringin content in a kind of gastrointestinal disease treating pill according to claim 1, the concentration that it is characterized in that described reference substance solution is 0.01mg/ml.
3. the assay method of naringin content in a kind of gastrointestinal disease treating pill according to claim 1 is characterized in that the described water-bath reflux time is 30 minutes.
4. the assay method of naringin content in a kind of gastrointestinal disease treating pill according to claim 1 is characterized in that described miillpore filter aperture is 0.45 μ m.
5. the assay method of naringin content in a kind of gastrointestinal disease treating pill according to claim 1, the concentration that it is characterized in that described glacial acetic acid aqueous solution is 0.3%.
6. the assay method of naringin content in a kind of gastrointestinal disease treating pill according to claim 1, the volume ratio that it is characterized in that described acetonitrile and glacial acetic acid is 20: 80, the concentration of described glacial acetic acid aqueous solution is 0.3%.
7. the assay method of naringin content in a kind of gastrointestinal disease treating pill according to claim 1 is characterized in that described flow velocity is 0.8ml/min.
8. the assay method of naringin content in a kind of gastrointestinal disease treating pill according to claim 1 is characterized in that described column temperature is 35 ℃.
CNB2005100148809A 2005-08-26 2005-08-26 Determination method of naringoside content in stomach intestine calm pill Active CN100350242C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100148809A CN100350242C (en) 2005-08-26 2005-08-26 Determination method of naringoside content in stomach intestine calm pill

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100148809A CN100350242C (en) 2005-08-26 2005-08-26 Determination method of naringoside content in stomach intestine calm pill

Publications (2)

Publication Number Publication Date
CN1758058A CN1758058A (en) 2006-04-12
CN100350242C true CN100350242C (en) 2007-11-21

Family

ID=36703536

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100148809A Active CN100350242C (en) 2005-08-26 2005-08-26 Determination method of naringoside content in stomach intestine calm pill

Country Status (1)

Country Link
CN (1) CN100350242C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101757293B (en) * 2008-12-24 2012-02-29 天津中新药业集团股份有限公司乐仁堂制药厂 Quality control method of gastrointestinal disease treating pill

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU740250A1 (en) * 1978-11-01 1980-06-15 Батумский Филиал Грузинского Научно-Исследовательского Института Пищевой Промышленности Method of preparing naringin
CN1487279A (en) * 2003-05-29 2004-04-07 江西江中药业股份有限公司 Quality detection method for compound pummelo exocarp prepn
CN1528773A (en) * 2003-09-29 2004-09-15 中山大学 Method for extracting shaddock ped aglycone from shaddock

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU740250A1 (en) * 1978-11-01 1980-06-15 Батумский Филиал Грузинского Научно-Исследовательского Института Пищевой Промышленности Method of preparing naringin
CN1487279A (en) * 2003-05-29 2004-04-07 江西江中药业股份有限公司 Quality detection method for compound pummelo exocarp prepn
CN1528773A (en) * 2003-09-29 2004-09-15 中山大学 Method for extracting shaddock ped aglycone from shaddock

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HPLC法测定驳骨丸中柚皮苷的含量 李雁玲,汤启勋.中药新药与临床药理,第15卷第1期 2004 *
酸橙柚皮苷的高效液相色谱测定研究 王四春,陈朝明.衡阳医学院学报,第23卷第1期 1995 *
高效液相色谱法测定杏苏咳水中柚皮苷的含量 李雁玲.广州中医药大学学报,第21卷第4期 2004 *

Also Published As

Publication number Publication date
CN1758058A (en) 2006-04-12

Similar Documents

Publication Publication Date Title
CN111337589A (en) Method for establishing orange-shell mixture HPLC fingerprint spectrum
CN103901123A (en) Method for detecting macromolecular substance in reduning injection
CN113252821B (en) Method for establishing fingerprint of flavonoid component in ginkgo leaf extraction intermediate or preparation thereof and fingerprint established by method
CN107064322B (en) HPLC wavelength switching method for simultaneously measuring contents of gallic acid and sanguisorbin I in sanguisorba or sanguisorba preparations
CN102854281A (en) Detection method of sugar-free strong loquat syrup
CN114935620A (en) Kit for simultaneously and quantitatively detecting 78 neuropsychiatric drugs
CN102441057B (en) High performance liquid chromatography (HPLC) fingerprint detection method for blood-nourishing brain-refreshing grain
CN101700262A (en) Quality control method of andrographis paniculata dropping pills
CN100350242C (en) Determination method of naringoside content in stomach intestine calm pill
CN110530990B (en) Detection method of caesalpinia-caesalpinia cold mixture
CN110806457B (en) Detection method of fingerprint of Sijun manna drink
CN101961405A (en) Method for testing content of pinoresinol diglucoside in compound eucommia bark tablet
CN104730167B (en) A kind of hydrochloric acid lorcaserin enantiomerism body detecting method and quality control standard thereof
CN102078503A (en) Detection method for pulse-activating decoction traditional Chinese medicine preparation
CN113567593B (en) Ginkgo honey ring oral solution multi-component content detection and fingerprint spectrum method construction thereof
WO2009155755A1 (en) Method for determining the contents of oligosaccharides in morinda officinalis
CN113820411A (en) Method for measuring contents of schizandrol A and schizandrol B in preparation for strengthening body resistance and removing blood stasis
CN113341007A (en) Method for measuring contents of multiple components in whole Chinese date seed nerve-soothing capsule based on HPLC (high performance liquid chromatography) characteristic spectrum
CN115728403A (en) Method for detecting enantiomer in levocarnitine
CN1731172A (en) Method for measuring Schizandrol A content in climacteric syndrome-relieving tablet
CN104931607A (en) Content measurement method for Lingqijia oral solution
CN112666278A (en) Limit detection method for strychnine in Huatuo reconstruction pills
CN101029890A (en) Method for inspecting Chinese-medicinal preparation Kaiyinwan
CN100360935C (en) Quality control method for Vitamin B1 in mind-tranquilizing brain-replenishing liquid
CN113791149B (en) Detection method of 1-chloro-3-methoxypropane related substance

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 300380 Yumen Road, Xiqing District, Tianjin

Patentee after: Lerentang Pharmaceutical Factory of Jinyao Darentang Group Co.,Ltd.

Address before: 300380 Yumen Road, Xiqing District, Tianjin

Patentee before: Letrentang pharmaceutical factory of Tianjin Zhongxin Pharmaceutical Group Co.,Ltd.

CP01 Change in the name or title of a patent holder